PRESS RELEASE

MolMed - at ASCO 2015 with three studies on the progress of NGR-hTNF therapy in mesothelioma

Milan (Italy), 14 May 2015 – MolMed S.p.A. (MLM.MI) announces that three studies on its investigational therapy NGR-hTNF have been accepted for presentation at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), that will take place in Chicago (IL, USA) from May 29th to June 2nd, 2015. Abstracts are now available on the ASCO 2015 website (http://am.asco.org/).

Once again an important number of MolMed studies have been accepted for presentation at the ASCO meeting confirming the quality of the NGR-hTNF clinical development program in malignant pleural mesothelioma, the tumour associated with exposure to asbestos.

The company is particularly pleased to announce that the double-blind randomised Phase III study results with NGR-hTNF in mesothelioma, already released in 2014, have been selected for an oral presentation in the section "*Lung Cancer - NSCLC local-regional / SCLC / Other Thoracic Cancers*". The presentation will highlight the results achieved in a large proportion of patients with more aggressive disease (corresponding to 50% of patients), defined on the basis of the treatment-free interval after first-line chemotherapy, though the primary endpoint was not met for the whole population. These patients with poorer prognosis disease had a statistically significant improvement of overall survival, coupled with a favourable drug tolerability profile. Two additional analyses related to data from the Phase III study were selected for poster presentations, confirming the clinical relevance of the results obtained in mesothelioma.

This evidence is particularly important as it sustains the rationale behind the efficacy of using NGR-hTNF in combination with gemcitabine reported in the randomized Phase II study in first line treatment of squamous non-small cell lung cancer. Moreover, these data are consistent with the hypothesized mechanism of action, based on the increased penetration of the chemotherapeutic agent thanks to the activity of NGR-hTNF on the newly formed tumour vasculature.

New data disclosed at ASCO will be announced in separate press releases during the meeting.

Presentation schedule at ASCO 2015

ABSTRACT #	ABSTRACT TITLE	PRESENTATION DATE & TIME (CDT)
7501	Phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM)	Saturday 30 May, 15:00 – 18:00 **
7557	Treatment-free interval after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): findings from the NGR015 phase 3 trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC	Monday 1 June, 8:00 - 11:00 *
7558	Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously treated patients with malignant pleural mesothelioma (MPM) enrolled in the NGR015 phase 3 trial	Monday 1 June, 08:00 - 11:00 *

** Poster presentation ** Oral presentation*

FROM GENES TO THERAPY

MOLMED S.p.A.
Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com
Share capital € 19,841,682.30 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue
General Manager Corporate Governance & Administration
Investor Relations Director *ad int.*
MolMed S.p.A.
phone: +39 02 21277.411
fax: +39 02 21277.325
e-mail: investor.relations@molmed.com

Press agent
Federico Ferrari
SEC Relazioni Pubbliche e Istituzionali srl
phone: +39 02 6249991 – mobile +39 347 6456873
e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.